Valuation : Keros Therapeutics, Inc.

Market Cap 220M 189M 179M 162M 305M 20.99B 306M 2.13B 819M 10.68B 825M 807M 33.74B P/E 2026 *
-2x
P/E 2027 * -1.78x
Enterprise Value 220M 189M 179M 162M 305M 20.99B 306M 2.13B 819M 10.68B 825M 807M 33.74B EV / Sales 2026 *
14.1x
EV / Sales 2027 * 16x
Free-Float
46.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week-2.12%
1 month+4.14%
3 months+10.25%
6 months-1.69%
Current year-45.58%
1 week 10.98
Extreme 10.98
11.82
1 month 10
Extreme 10
11.82
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 30/11/2015
Director of Finance/CFO 55 02/08/2026
Chief Tech/Sci/R&D Officer 53 31/05/2019
Director TitleAgeSince
Chairman 70 30/06/2024
Director/Board Member 63 31/03/2016
Director/Board Member 50 29/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Executive/Senior Manager

-3,568 0.0180%
18/08/26 Sell

General Counsel

-4,485 0.0227%
18/08/26 Sell

Chief Financial Officer

-1,224 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-2.12%-29.70%-69.65% 221M
-2.11%-3.44%+41.04%+98.48% 68.24B
-0.23%-4.45%+30.39%+73.64% 62.23B
+1.67%+2.47%-11.23%+388.34% 27.8B
-1.05%-7.30%+25.00%+12.31% 24.86B
+0.34%-6.78%-7.27%-17.99% 24.22B
+0.43%-4.78%+18.26%-20.61% 19.36B
-3.03%-5.19%+192.88%+340.13% 17.28B
-1.94%-6.36%-7.05%+516.16% 14.46B
-2.28%-4.90%+43.64%+155.21% 14.23B
Average -0.90%-3.51%+29.60%+147.60% 27.29B
Weighted average by Cap. -0.86%-3.80%+33.07%+135.96%

Financials

2026 *2027 *
Net sales 15.57M 13.41M 12.7M 11.51M 21.6M 1.49B 21.7M 151M 58M 757M 58.46M 57.18M 2.39B 13.73M 11.83M 11.2M 10.15M 19.04M 1.31B 19.14M 133M 51.14M 667M 51.55M 50.42M 2.11B
Net income -110M -95.08M -90.03M -81.6M -153M -10.54B -154M -1.07B -411M -5.36B -414M -405M -16.95B -147M -127M -120M -109M -204M -14.08B -206M -1.43B -549M -7.16B -554M -541M -22.64B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
11/09/26 US$11.08 -0.81% 143,825
10/09/26 US$11.17 -1.24% 128,791
09/09/26 US$11.31 +1.25% 188,507
08/09/26 US$11.17 -1.33% 73,047
04/09/26 US$11.32 +1.89% 65,636
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.08USD
Average target price
19.83USD
Spread / Average Target
+79.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!